NEK9

Across TCGA pan-cancer cohorts, NEK9 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of NEK9’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where NEK9 RNA is repressed in tumor relative to normal tissue. In most cancer types NEK9 is over-expressed in tumor, although a few such as THCA and UCEC show the opposite, repressed pattern.

THCA, HNSC, and LIHC are the cancer types where NEK9 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NEK9 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	II,III,IV	−0.850	<.001	10	view →
HNSC	All	III,IV	+0.606	<.001	9	view →
LIHC	Female	II,III,IV	+1.019	<.001	8	view →
UCEC	All	All	−1.323	<.001	6	view →
BRCA	Female	All	−0.430	<.001	6	view →
BLCA	Male	IV	−1.475	.004	5	view →
KIRC	All	II,III,IV	−0.342	<.001	5	view →
CHOL	All	All	+0.904	.001	4	view →
ESCA	Female	All	+0.569	.030	1	view →
KICH	All	All	−0.380	.027	1	view →
LUAD	All	All	−0.180	.037	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

NEK9–THCA

Open the THCA breakdown →